Document Detail


Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment.
MedLine Citation:
PMID:  17893967     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We studied the large and small artery elasticity (AE) and systemic vascular resistance (SVR) of systemic lupus erythematosus (SLE) patients according to treatment profile. Forty-one SLE patients (90% female, mean age 48.7 +/- 2.4 years) were compared to 96 healthy controls. The large and small AE and the SVR were derived from radial artery waveforms (model CR-2000, HDI Inc.). Patients were categorized into groups according to treatment: steroid (12), hydroxychloroquine (HCQ) (9), steroid+HCQ (16), and no-steroids-no-HCQ (4). The steroid group had reduced large AE and increased SVR as compared to the HCQ group (8.3 mmHg x mL x 10 and 18.4 dyne x sec x 10(-3) versus 13.7 and 14.4, respectively). Mean large AE and the SVR of the HCQ group was similar to that of the controls (11.8 mmHg x mL x 10 and 14.5 dyne x sec x 10(-3), respectively). Mean large AE and SVR of the steroid+HCQ group were better than the steroid group (10.4 mmHg x mL x 10 and 16.0 dyne x sec x 10(-3)). Patients that received steroids had higher rates of hypertension (36%) and diabetes (1%) compared to rest of the patients (15% and 0%, respectively). Small AE, blood pressure, CRP, and SLEDAI were similar between the groups. Among SLE patients, steroid treatment was associated with the highest degree of vascular damage, and HCQ was associated with the lowest degree of vascular damage. It is possible that the steroids are responsible in part to the increased large-vessel manifestations observed in these patients, and that HCQ might have a protective effect on the vessel wall.
Authors:
Amir Tanay; Eyal Leibovitz; Angela Frayman; Reuven Zimlichman; Marina Shargorodsky; Dov Gavish
Related Documents :
12735337 - Hla-b8 in raynaud's phenomenon.
17642847 - Clinico-epidemiological study of hiv patients in trivandrum.
11059857 - Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a ...
2758727 - Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month st...
19593227 - Takayasu arteritis and giant cell arteritis: a spectrum within the same disease?
8348397 - Unilateral "vanishing psoas": an anatomic variant.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1108     ISSN:  0077-8923     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-09-25     Completed Date:  2007-10-30     Revised Date:  2007-12-10    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  24-34     Citation Subset:  IM    
Affiliation:
Rheumatology Unit, Wolfson Medical Center, Holon, Israel. tanai@post.tau.ac.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / adverse effects*
Antirheumatic Agents / therapeutic use*
Arteries / drug effects
Diabetes Mellitus
Elasticity / drug effects
Female
Humans
Hydroxychloroquine / therapeutic use*
Hypertension / complications
Lupus Erythematosus, Systemic / complications,  drug therapy*
Male
Middle Aged
Muscle, Smooth, Vascular / drug effects*
Vascular Resistance / drug effects
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Antirheumatic Agents; 118-42-3/Hydroxychloroquine
Comments/Corrections
Erratum In:
Ann N Y Acad Sci. 2007;1114:464
Note: Shargorodsky, Marina [added]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosu...
Next Document:  Sun-induced life-threatening lupus nephritis.